Company:  SESEN BIO, INC. (SESN)
Form Type:  10-Q
Filing Date:  11/12/2019 
CIK:  0001485003 
Address:  245 FIRST STREET
SUITE 1800
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-444-8550 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.57  
Change: 
-0.0493 (-8.02%)  
Trade Time: 
Mar 27  
Market Cap: 
$62.25M
Trade SESN now with 

© 2020  
Description of Business
We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody.
Register and access this filing in:     
  FORM 10-Q
    PART I
      Item 2. Management's Discussion and Analysis of Financial ...
    PART II - OTHER INFORMATION
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements.
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 3. Quantitative and Qualitative Disclosures About ...
    PART II
      Item 1. Legal Proceedings.
      Item 1A. Risk Factors.
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO